In a filing, EyePoint Pharmaceuticals Inc revealed its Chief Medical Officer Ribeiro Ramiro unloaded Company’s shares for reported $31602.0 on Nov 11 ’25. In the deal valued at $11.61 per share,2,722 shares were sold. As a result of this transaction, Ribeiro Ramiro now holds 0 shares worth roughly $0.0.
Then, Ramiro Ribeiro bought 2,722 shares, generating $30,895 in total proceeds.
Before that, Zaderej Karen L. bought 5,000 shares. EyePoint Pharmaceuticals Inc shares valued at $29,950 were divested by the Director at a price of $5.99 per share. As a result of the transaction, Zaderej Karen L. now holds 36,500 shares, worth roughly $0.51 million.
RBC Capital Mkts initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to an Outperform in a research note published on June 17, 2025; the price target was $28. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Scotiabank began covering EYPT with “Sector outperform” recommendation on October 16, 2024. Jefferies started covering the stock on August 28, 2024. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Tuesday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock jump 6.28% to $13.96. Over the last five days, the stock has gained 19.88%. EyePoint Pharmaceuticals Inc shares have risen nearly 33.08% since the year began. Nevertheless, the stocks have risen 87.38% over the past one year. While a 52-week high of $14.91 was reached on 09/30/25, a 52-week low of $3.91 was recorded on 04/09/25.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 13.09, which if violated will result in even more drops to 12.22. On the upside, there is a resistance level at 14.69. A further resistance level may holdings at 15.42.
How much short interest is there in EyePoint Pharmaceuticals Inc?
A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on 2025-10-31, dropping by -0.44 million shares to a total of 7.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 8.0 million shares. There was a decline of -5.88%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 22, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $35 price target.
